You are here

  • Home
  • Archive
  • Volume 9, Issue 12
  • Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

Article metrics

Article menu

Download PDFPDF

XML
Health economics
Original research
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

 

Online download statistics by month:

Online download statistics by month: December 2019 to April 2024

AbstractFullPdf
Dec 201931431099
Jan 202016015347
Feb 202013913833
Mar 202013212759
May 2020626029
Jun 2020625845
Jul 2020414013
Aug 2020464241
Sep 2020585434
Oct 2020847725
Nov 2020514131
Dec 2020372832
Jan 2021514432
Feb 2021484525
Mar 2021403727
Apr 2021434319
May 2021443924
Jun 202132319
Jul 2021604716
Aug 2021383223
Sep 2021525414
Oct 2021514332
Nov 2021565027
Dec 2021747134
Jan 2022697023
Feb 2022292516
Mar 2022746529
Apr 2022575314
May 2022484926
Jun 2022585025
Jul 2022282913
Aug 2022242310
Sep 2022353318
Oct 2022525126
Nov 2022565324
Dec 2022464317
Jan 2023374219
Feb 2023433715
Mar 2023474824
Apr 2023454523
May 2023413821
Jun 2023383214
Jul 2023575215
Aug 2023343412
Sep 2023252512
Oct 2023484918
Nov 2023434417
Dec 2023494719
Jan 2024363613
Feb 2024545328
Mar 2024595354
Apr 2024595953
Total306629021368